[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 69 of about 69
1. Omlin A, D'Addario G, Gillessen S, Cerny T, von Hessling A, Früh M: Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer; 2009 Sep;65(3):383-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung.
  • A 53-year-old woman was with adenocarcinoma of the lung metastatic to the brain was treated after several lines of chemotherapy with pemetrexed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375814.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


2. Hata A, Nanjo S, Otsuka K, Kida Y, Higashi Y, Kaji R, Fujita S, Katakami N: [Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies]. Gan To Kagaku Ryoho; 2009 May;36(5):807-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of effective S-1 monotherapy for patients with metastatic adenocarcinoma of the lung after multiple previous chemotherapies].
  • She was diagnosed as having lung adenocarcinoma with multiple metastases (cT4N0M1, stage IV, mucinous BAC)in June, 2004.
  • She was diagnosed as having lung adenocarcinoma with multiple metastases(cT4N3M1, stage IV)in October, 2004.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461182.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


3. Su YC, Hsu YC, Chai CY: Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J Med Sci; 2006 Jan;22(1):14-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma.
  • Thyroid transcription factor-1 (TTF-1), and cytokeratin 7 (CK7) and cytokeratin 20 (CK20) have recently been reported to be useful to distinguish between primary and metastatic lung adenocarcinoma.
  • The aim of this study was to determine the usefulness of the staining patterns of pulmonary adenocarcinoma with antibodies to TTF-1, CK7, and CK20 in differentiating primary from metastatic pulmonary adenocarcinoma.
  • Of the 66 lung adenocarcinoma specimens that were enrolled in our study, there were 40 primary lung adenocarcinomas, 12 metastatic adenocarcinomas from breast, 13 metastatic adenocarcinomas from colon, and 1 metastatic adenocarcinoma from stomach.
  • We found that 73% of primary lung adenocarcinomas expressed TTF-1, whereas all nonpulmonary adenocarcinomas lacked TTF-1 staining.
  • In contrast, CK20 expression was significantly more prevalent in adenocarcinoma that originated in the GI tract than that of pulmonary or breast origin (p < 0.001).
  • A combination of TTF-1+CK7+CK20- was highly significantly associated with primary adenocarcinoma of lung (vs GI tract, p < 0.001; vs breast, p < 0.001).
  • A combination of TTF-1-CKCK20+ was highly significantly associated with adenocarcinoma of GI origin (vs lung, p < 0.001; vs breast, p < 0.001).
  • Our study has confirmed that expression of CK7, CK20, and TTF-1 is a useful immunohistochemical marker for diagnosis of lung tumors and for differential diagnosis of primary pulmonary adenocarcinomas from extrapulmonary adenocarcinomas metastatic to the lung.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Keratins / analysis. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570563.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins
  •  go-up   go-down


Advertisement
4. Nabili V, Natarajan S, Hirschovitz S, Bhuta S, Abemayor E: Collision tumor of thyroid: metastatic lung adenocarcinoma plus papillary thyroid carcinoma. Am J Otolaryngol; 2007 May-Jun;28(3):218-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of thyroid: metastatic lung adenocarcinoma plus papillary thyroid carcinoma.
  • We present a case of a collision tumor of metastatic lung adenocarcinoma and papillary thyroid carcinoma occurring in the thyroid gland of a 63-year-old woman who presented with a multinodular central neck mass.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Papillary / pathology. Lung Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17499145.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev; 2009 Sep 15;23(18):2140-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic disease is a primary cause of cancer-related death, and factors governing tumor cell metastasis have not been fully elucidated.
  • Here, we address this question by using tumor cell lines derived from mice that develop metastatic lung adenocarcinoma owing to expression of mutant K-ras and p53.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Oct 25;26(49):6979-88 [17486063.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Cell Cycle. 2008 Mar 1;7(5):570-2 [18256538.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] PLoS One. 2008;3(5):e2220 [18493606.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]
  • [Cites] EMBO Rep. 2008 Jun;9(6):582-9 [18483486.001]
  • [Cites] PLoS One. 2008;3(8):e2888 [18682804.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4078-85 [18757322.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7846-54 [18829540.001]
  • [Cites] RNA. 2008 Nov;14(11):2290-6 [18812437.001]
  • [Cites] RNA Biol. 2008 Jul-Sep;5(3):115-9 [19182522.001]
  • [Cites] PLoS One. 2009;4(4):e5401 [19404390.001]
  • [Cites] Genes Dev. 2009 Sep 15;23(18):2152-65 [19759263.001]
  • [Cites] Oncogene. 2007 Oct 18;26(48):6896-904 [17486075.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4174-9 [10760284.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):167-71 [11175784.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):785-92 [11533657.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Genes Chromosomes Cancer. 1991 May;3(3):168-88 [1651103.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1353-62 [1679529.001]
  • [Cites] J Cell Biol. 1991 Dec;115(5):1383-95 [1955479.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):665-74 [8616758.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6 [9843973.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]
  • [Cites] Cell. 2004 Dec 17;119(6):847-60 [15607980.001]
  • [Cites] Cell. 2004 Dec 17;119(6):861-72 [15607981.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2375-85 [15674322.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):548-58 [16098727.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10280-8 [16288016.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2105-12 [16288213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2746-51 [16477010.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):39-50 [16843264.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Nat Genet. 2007 May;39(5):582-3 [17460676.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):894-907 [18381893.001]
  • (PMID = 19759262.001).
  • [ISSN] 1549-5477
  • [Journal-full-title] Genes & development
  • [ISO-abbreviation] Genes Dev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA117965; United States / NCI NIH HHS / CA / P50 CA70907; United States / NCI NIH HHS / CA / R01 CA129632; United States / NCI NIH HHS / CA / P30 CA125123; United States / NCI NIH HHS / CA / 5 T32 CA009666; United States / NCI NIH HHS / CA / R01 CA132608; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / T32 CA009666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Mirn200 microRNA, mouse; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2751985
  •  go-up   go-down


6. Kai N, Ishii H, Morinag R, Sonoda H, Oka H, Amemiya Y, Iwata A, Otani S, Umeki K, Sakashita H, Kadota J: [Pulmonary adenocarcinoma with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):304-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary adenocarcinoma with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor].
  • A computed tomographic scan of the chest showed a lung mass in the left lower lobe, which was thereafter diagnosed as adenocarcinoma.
  • An immunohistochemical examination of the tissue specimen obtained from the left temporal bone revealed evidence of metastatic adenocarcinoma from the lung.
  • No other metastatic lesions including separate site of bone were seen.
  • This is a very rare case of lung cancer with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Facial Paralysis / etiology. Lung Neoplasms / pathology. Skull Neoplasms / secondary. Temporal Bone

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455960.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, Truskinovsky AM, Dudek AZ: Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer; 2010 Sep 1;11(5):E1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
  • Activating mutations in the epidermal growth factor receptor (EGFR) gene are extremely rare in small-cell lung cancer (SCLC).
  • Here, we present a case of an EGFR-mutant gefitinib-responsive non-small-cell lung cancer (NSCLC) of adenocarcinoma histology occurring in a never-smoker followed by subsequent diagnosis of metastatic SCLC carrying an EGFR mutation.
  • Although gefitinib therapy of the primary NSCLC resulted in disease control for over 3 years, the patient subsequently developed metastatic SCLC to the liver.
  • Epidermal growth factor receptor mutation analysis revealed that the exon 21 L858R activating mutation was present in both the original lung adenocarcinoma and the metastatic SCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Small Cell / genetics. Lung Neoplasms / genetics. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Aged. Female. Humans. Liver Neoplasms / secondary. Mutation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20837450.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


8. Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, Ashkenazi K, Goren E, Meiri E, Morgenstern S, Perelman M, Barshack I, Goren Y, Edmonston TB, Chajut A, Aharonov R, Bentwich Z, Rosenfeld N, Cohen D: A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn; 2010 Nov;12(6):771-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The definitive identification of malignant pleural mesothelioma (MPM) has significant clinical implications, yet other malignancies often involve the lung pleura, confounding the diagnosis of MPM.
  • In the absence of accurate markers, MPM can be difficult to distinguish from peripheral lung adenocarcinoma and metastatic epithelial cancers.
  • Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas that frequently metastasize to lung pleura.
  • The assay reached a sensitivity of 100% and a specificity of 94% in a blinded validation set of 68 samples from the lung and pleura.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):43-50 [11145250.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6315-21 [19638575.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] J Clin Pathol. 2001 Oct;54(10):766-70 [11577123.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1409-19 [9414184.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):766-70 [15965474.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Ultrastruct Pathol. 2006 Jan-Feb;30(1):3-17 [16517466.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3687-92 [16505370.001]
  • [Cites] Crit Rev Toxicol. 2006 Feb;36(2):165-87 [16736942.001]
  • [Cites] Nature. 2006 Jun 1;441(7093):589-94 [16688184.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5129-35 [16951230.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):255-63 [17075562.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):1-16 [17056092.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):731-43 [17540598.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):894-907 [18381893.001]
  • [Cites] Nat Biotechnol. 2008 Apr;26(4):462-9 [18362881.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]
  • [Cites] Curr Opin Pulm Med. 2008 Jul;14(4):303-9 [18520263.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jul;132(7):1062-72 [18605762.001]
  • [Cites] Mod Pathol. 2008 Sep;21(9):1084-94 [18587319.001]
  • [Cites] PLoS One. 2008;3(9):e3148 [18773077.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7846-54 [18829540.001]
  • [Cites] Curr Treat Options Oncol. 2008 Jun;9(2-3):147-57 [18709470.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2030-7 [19273703.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):615-23 [19396864.001]
  • [Cites] Arch Pathol Lab Med. 2009 Aug;133(8):1317-31 [19653732.001]
  • [Cites] Clin Cancer Res. 2010 Jan 15;16(2):610-9 [20068099.001]
  • [Cites] Am J Respir Cell Mol Biol. 2010 Mar;42(3):312-9 [19502386.001]
  • [Cites] Mod Pathol. 2010 Jun;23(6):814-23 [20348879.001]
  • [Cites] Pathol Res Pract. 2010 Aug 15;206(8):578-84 [20418022.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):375-83 [18624795.001]
  • [Cites] Ind Health. 2001 Apr;39(2):183-5 [11341549.001]
  • (PMID = 20864637.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2963911
  •  go-up   go-down


9. Ferté C, Besse B, Dansin E, Parent F, Buisine MP, Copin MC, Penel N, Soria JC: Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Ann Oncol; 2010 Jun;21(6):1385-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501506.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 22
  •  go-up   go-down


10. Takagi Y, Nakamura H, Miwa K, Adachi Y, Fujioka S, Haruki T, Taniguchi Y: A case of G-CSF-producing invasive apical cancer resected following preoperative adjuvant therapy. Thorac Cardiovasc Surg; 2010 Aug;58(5):304-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A very small nodule was noted in the right frontal lobe on brain MRI before surgery, and the final diagnosis was pT3N0M1, stage IV lung adenocarcinoma.
  • The prognosis for G-CSF-producing lung cancer and invasive apical cancer is poor.
  • This was a rare and difficult case of lung cancer showing both characteristics of lung cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / blood. Lung Neoplasms / therapy. Lymph Node Excision. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 20680910.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


11. Becerra CR, Verma UN, Tran HT, Tavana D, Williams NS, Frenkel EP: Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. Am J Clin Oncol; 2008 Jun;31(3):219-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study determined the maximum-tolerated dose (MTD), toxicity, and pharmacokinetics of irinotecan (CPT-11), capecitabine, and epirubicin in patients with metastatic adenocarcinoma of lung, breast, or gastrointestinal tract.
  • METHODS: Eligibility criteria included the following: documented adenocarcinoma of the lung, breast, or gastrointestinal tract, <3 prior chemotherapy regimens, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, age > or =18 years, adequate organ function, and signed informed consent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Epirubicin / administration & dosage. Gastrointestinal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Topoisomerase II Inhibitors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525298.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Topoisomerase II Inhibitors; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Kurt M, Onal IK, Elkiran T, Altun B, Altundag K, Gullu I: Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma. Med Oncol; 2005;22(2):203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma.
  • We report the case of a 52-yr-old man with metastatic lung adenocarcinoma who developed tumor lysis syndrome after administration of zoledronic acid.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Diphosphonates / adverse effects. Imidazoles / adverse effects. Lung Neoplasms / pathology. Tumor Lysis Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Jun 15;100(12):2613-21 [15197804.001]
  • [Cites] Med Oncol. 2001;18(2):149-51 [11778761.001]
  • [Cites] Mayo Clin Proc. 2002 Jul;77(7):722-8 [12108612.001]
  • [Cites] Am J Med. 1997 Nov;103(5):363-7 [9375703.001]
  • [Cites] Am J Med Sci. 2003 Jan;325(1):38-40 [12544084.001]
  • [Cites] J Korean Med Sci. 2001 Feb;16(1):115-8 [11289389.001]
  • [Cites] Am J Clin Oncol. 2000 Oct;23(5):491-3 [11039510.001]
  • [Cites] Int J Hematol. 2004 Jan;79(1):37-43 [14979476.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Mar;51(3):187-92 [12655435.001]
  • [Cites] Int J Hematol. 2003 Dec;78(5):443-9 [14704038.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):521-4 [8341221.001]
  • [Cites] Am J Clin Oncol. 1995 Feb;18(1):71-3 [7847263.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1459-68 [10780527.001]
  • [Cites] BJU Int. 2004 Jul;94(1):164-70 [15217454.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 21):3-11 [12584689.001]
  • [Cites] Leukemia. 2000 May;14(5):841-4 [10803515.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):474-5 [12393987.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12 ):1971-8 [12799645.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2211-21 [11092402.001]
  • (PMID = 15965285.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


13. Okudera K, Takanashi S, Hayashi A, Morimoto T, Nakamura K, Mikuniya M, Dempoya J, Okumura K: [A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen]. Gan To Kagaku Ryoho; 2009 Nov;36(11):1889-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
  • After further examinations, he was diagnosed with stage IV adenocarcinoma of the lung.
  • No severe side effects were observed, and an antitumor action was achieved over a relatively long period.
  • Therefore, it was suggested that a single administration of S-1 for non-small cell lung cancer, which had been treated with other multiple regimens, is safe, and long-term control of the disease can be expected.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920394.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Quinazolines; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; S65743JHBS / gefitinib
  •  go-up   go-down


14. Tham CK, Choo SP, Lim WT, Toh CK, Leong SS, Tan SH, Li HH, Tan EH: Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis. J Thorac Oncol; 2009 Aug;4(8):988-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
  • INTRODUCTION: Randomized placebo-controlled phase III trials failed to show a survival benefit with the addition of gefitinib to platinum-based combination chemotherapy as first-line therapy in unselected patients with advanced non-small cell lung cancer (NSCLC).
  • METHODS: Never-smoker patients with chemonaive stage IIIB or IV NSCLC were treated with GCI.
  • Most patients were women, and adenocarcinoma was the most common histologic subtype.
  • A prospective randomized phase III study is needed to confirm this finding.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546820.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; S65743JHBS / gefitinib
  •  go-up   go-down


15. Cadranel J, Lavolé A, Gounant V, Wislez M: [Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum]. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S158-16S163
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum].
  • [Transliterated title] Formes cliniques des cancers thoraciques. Carcinome bronchiolo-alvéolaire (CBA) et adénocarcinome pulmonaire avec composante bronchiolo-alvéolaire (ADC-CBA): un continuum anatomo-clinique.
  • Bronchioloalveolar carcinoma (BAC) is a primary pulmonary adenocarcinoma (ADC) arising in the cells of the terminal respiratory unit.
  • Although stage IIIB and IV tumours were excluded from the strict WHO definition of BAC the first international workshop on this tumour in 2004 emphasised the clinico-pathological continuum that exists between BAC as defined by WHO and ADC with BAC features (ADC-BAC).
  • The high frequency of epidermal growth factor receptor (EGFR) expression and amplification and/or mutation of its gene, as well as the finding in some cases of a major response to EGFR tyrosine-kinase inhibitors, have lead to several therapeutic trials of these drugs.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268353.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 30
  •  go-up   go-down


16. Mego M, Sycova-Mila Z, Martanovic P, Liskova S, Obertova J, Mardiak J: Inflammatory skin metastasis as a first sign of progression of lung cancer--a case report. Klin Onkol; 2010;23(6):449-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory skin metastasis as a first sign of progression of lung cancer--a case report.
  • ICM in lung cancer are extremely rare and often misdiagnosed.
  • PATIENTS AND METHODS: We report on a 55-year-old man with metastatic lung adenocarcinoma and bone metastases in the axial skeleton and left humerus diagnosed in August 2008.
  • RESULTS: Skin biopsy revealed skin infiltration by poorly differentiated carcinoma compatible with a primary lung tumour.
  • CONCLUSION: Metastasis of lung carcinoma could be one of the causes of inflammatory skin lesions in cancer patients and these metastases should be considered in cancer patients with persisting cutaneous lesions with signs of inflammation and no response to antibiotic therapy.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21348413.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


17. Yakan S, Caliskan C, Makay O, Denecli AG, Korkut MA: Intussusception in adults: clinical characteristics, diagnosis and operative strategies. World J Gastroenterol; 2009 Apr 28;15(16):1985-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among enteric intussusceptions, 14 were secondary to a benign process, and in one of these, the malignant cause was secondary to metastatic lung adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2000 Jan-Feb;25(1):45-7 [10652920.001]
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1941-9 [17846839.001]
  • [Cites] J Clin Gastroenterol. 2003 Jan;36(1):18-21 [12488701.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Feb;13(1):39-41 [12598757.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Aug;13(4):280-2 [12960794.001]
  • [Cites] ANZ J Surg. 2003 Dec;73(12):1044-7 [14632903.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Dec;13(6):394-6 [14712104.001]
  • [Cites] Abdom Imaging. 2004 Jan-Feb;29(1):42-4 [15160752.001]
  • [Cites] Am J Surg. 1971 May;121(5):531-5 [5557762.001]
  • [Cites] Am J Surg. 1976 Jun;131(6):758-61 [937658.001]
  • [Cites] Gastrointest Endosc. 1986 Jun;32(3):217-8 [3721141.001]
  • [Cites] Am J Surg. 1989 Jul;158(1):25-8 [2662787.001]
  • [Cites] S Afr Med J. 1990 Mar 17;77(6):313-4 [2315816.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):509-11 [2227328.001]
  • [Cites] Gastrointest Radiol. 1991 Summer;16(3):264-6 [1879648.001]
  • [Cites] Langenbecks Arch Chir. 1993;378(5):288-91 [8412437.001]
  • [Cites] J Clin Gastroenterol. 1995 Oct;21(3):257 [8648067.001]
  • [Cites] Am J Surg. 1997 Feb;173(2):88-94 [9074370.001]
  • [Cites] Ann Surg. 1997 Aug;226(2):134-8 [9296505.001]
  • [Cites] Magn Reson Imaging. 1997;15(9):1095-8 [9364957.001]
  • [Cites] Clin Radiol. 1998 Jan;53(1):53-7 [9464437.001]
  • [Cites] J Am Coll Surg. 1999 Apr;188(4):390-5 [10195723.001]
  • [Cites] Radiology. 1999 Sep;212(3):853-60 [10478257.001]
  • [Cites] Postgrad Med J. 2005 Mar;81(953):174-7 [15749793.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2005 Apr;15(2):173-5 [15898912.001]
  • [Cites] Int J Colorectal Dis. 2006 Dec;21(8):834-9 [15951987.001]
  • [Cites] Dig Dis Sci. 2007 Mar;52(3):764-6 [17268836.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Nov;22(11):1767-71 [17914948.001]
  • [Cites] J Clin Ultrasound. 2002 Jan;30(1):48-51 [11807856.001]
  • (PMID = 19399931.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2675089
  •  go-up   go-down


18. Kanaji N, Bandoh S: [Hand-foot syndrome associated with uracil/tegafur and docetaxel in a patient with lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2007 Jun;45(6):474-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hand-foot syndrome associated with uracil/tegafur and docetaxel in a patient with lung cancer].
  • A 30-year-old woman given a diagnosis of stage IV lung adenocarcinoma, was admitted to our hospital because of chest pain due to pleuritis carcinomatosa.
  • Since these drugs play a crucial role in lung cancer treatment, we need to pay attention to hand-foot syndrome.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lung Neoplasms / drug therapy. Taxoids / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644943.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 56HH86ZVCT / Uracil
  •  go-up   go-down


19. Moore A, Lau E, Yang C, Mackool B, Kuter DJ: Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma. Am J Clin Oncol; 2007 Jun;30(3):329-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Anticoagulants / adverse effects. Dalteparin / adverse effects. Lung Neoplasms / complications. Skin Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551316.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; S79O08V79F / Dalteparin
  •  go-up   go-down


20. Khan O, Tong WP, Karlin NJ: Metastatic lung adenocarcinoma in a 20-year-old patient. Curr Oncol; 2010 Feb;17(1):56-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lung adenocarcinoma in a 20-year-old patient.
  • Lung cancer is rare disease in patients under 25 years of age.
  • He was treated for pneumonia after a chest radiograph showed total opacification of the right lung.
  • Further imaging studies showed diffuse metastatic disease.
  • Tissue immunostaining confirmed a non-small-cell lung cancer.
  • In this paper, we hope to illustrate the unique challenges in diagnosing and treating young patients with metastatic lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1989 Mar;47(3):391-3 [2467630.001]
  • [Cites] Chest. 2001 Jul;120(1):32-6 [11451812.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1837-41 [10760760.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Chest. 1992 Dec;102(6):1723-9 [1446479.001]
  • [Cites] Onkologie. 2008 Jun;31(6):305-8 [18547970.001]
  • [Cites] Mayo Clin Proc. 2008 May;83(5):584-94 [18452692.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1730-3 [10223566.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jul;132(7):1079-103 [18605764.001]
  • (PMID = 20179804.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2826778
  • [Keywords] NOTNLM ; Metastatic lung cancer / non-small-cell lung cancer / young patients
  •  go-up   go-down


21. Herbst J, Jenders R, McKenna R, Marchevsky A: Evidence-based criteria to help distinguish metastatic breast cancer from primary lung adenocarcinoma on thoracic frozen section. Am J Clin Pathol; 2009 Jan;131(1):122-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based criteria to help distinguish metastatic breast cancer from primary lung adenocarcinoma on thoracic frozen section.
  • The distinction between primary lung adenocarcinoma and metastatic breast carcinoma in patients with a history of breast cancer is difficult by frozen section (FS) analysis.
  • The pretest odds ratio of primary pulmonary carcinoma/metastatic breast carcinoma was 2.6.
  • The incidence of 12 histopathologic features was assessed in a "training set" composed of 20 FSs, 10 with primary lung adenocarcinoma and 10 with metastatic breast cancer.
  • A differential diagnosis model composed of significant pathologic features that favor the diagnosis of primary lung adenocarcinoma (acini, lepidic growth, nuclear pseudoinclusions, and scar) or metastatic breast carcinoma (comedonecrosis, solid nests, trabecular architecture, and cribriform growth) was identified.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / pathology. Frozen Sections / methods. Lung Neoplasms / diagnosis


22. Ishida M, Nakama T, Shimazaki T, Tanaka T, Tsuchihashi Y, Morimoto K: [An autopsied case of pulmonary clear cell adenocarcinoma]. Nihon Kokyuki Gakkai Zasshi; 2010 May;48(5):364-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsied case of pulmonary clear cell adenocarcinoma].
  • We report a case of a 72-year-old woman who died of primary lung clear cell adenocarcinoma.
  • Sputum cytology and further diagnostic tests revealed stage IV lung adenocarcinoma.
  • According to previous reports in the literature, cases of primary lung clear cell adenocarcinoma are very rare.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20560438.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z: Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer; 2007 Sep;57(3):359-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
  • BACKGROUND: Lung cancer is the leading cause of cancer deaths in most countries.
  • Data from large phase II trials of non-small cell lung cancer (NSCLC) suggested that the histologic subtype of adenocarcinoma may be a prognostic factor for patients treated with gefitinib.
  • To evaluate the efficacy of gefitinib in palliative therapy for advanced patients with adenocarcinoma and brain metastases, we conducted a phase II study.
  • PATIENTS AND METHODS: Eligible patients had histologically confirmed adenocarcinoma and brain metastases confirmed with radiological studies.
  • CONCLUSIONS: Our data suggest that gefitinib has promising activity in palliative therapy for patients with advanced lung adenocarcinoma and brain metastasis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary. Lung Neoplasms / drug therapy. Palliative Care. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434236.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


24. Lee DH, Han JY, Yu SY, Kim HY, Nam BH, Hong EK, Kim HT, Lee JS: The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J Thorac Oncol; 2006 Nov;1(9):965-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study.
  • PURPOSE: This prospective trial was conducted to evaluate the role of gefitinib in never-smokers with advanced or metastatic adenocarcinoma of the lung.
  • PATIENTS AND METHODS: The main inclusion criteria were stage IIIB/IV adenocarcinoma of the lung and status as a lifetime never-smoker.
  • CONCLUSION: Gefitinib showed very promising antitumor activity and survival outcome in Korean never-smokers with adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Neoplasm Invasiveness / pathology. Quinazolines / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409980.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


25. Baldini E, Prochilo T, Boldrini L, Melfi F, Fontanini G: Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation. Mol Med Rep; 2008 Jan-Feb;1(1):41-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation.
  • Many EGFR-targeted agents, especially tyrosine-kinase inhibitors (TKIs), are being developed for the treatment of advanced non-small cell lung cancer (NSCLC) in which EGFR shows an activating mutation in the tyrosine-kinase domain.
  • Here, we report the management of a stage IV adenocarcinoma of the lung in a young non-smoking woman treated with gefitinib whose tumor developed EGFR-TKI resistance.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21479375.001).
  • [ISSN] 1791-2997
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


26. Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E: EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J; 2009 Feb;33(2):436-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
  • The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib improves survival of lung cancer as second- or third-line therapy.
  • The present study reports the case of a 27-yr-old nonsmoking male presenting with a metastatic lung adenocarcinoma with EGFR exon 19 deletion, associated with sensitivity to EGFR-TKI.
  • The present report underscores the interest of molecular monitoring in lung cancer.
  • Questions remain concerning the selection of sub-clones during epidermal growth factor receptor tyrosine kinase inhibitor therapy, which could differ according to metastatic sites, especially in the central nervous system.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Central Nervous System Neoplasms / secondary. Central Nervous System Neoplasms / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19181917.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


27. Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E, Yokota J: Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer; 2006 Sep 15;119(6):1491-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent EGFR mutations in brain metastases of lung adenocarcinoma.
  • Lung adenocarcinomas often metastasize to the brain, and the prognosis of patients with brain metastases is still very poor.
  • The epidermal growth factor receptor (EGFR) gene is mutated in a considerable fraction of primary lung adenocarcinomas, in particular those with drastic response to EGFR tyrosine kinase inhibitors.
  • EGFR mutations were detected in 12 of 19 metastatic lung adenocarcinomas to the brain (63%).
  • This frequency was higher than those in previous studies for EGFR mutations at various stages of lung adenocarcinoma in East Asia, including Japan (i.e., 20-55%).
  • In 6 cases with EGFR mutations, the corresponding primary lung tumors were also examined for the mutations, and in all of them, the same types of EGFR mutations were detected also in the primary tumors.
  • In 2 of them, second metastatic brain tumors in addition to the first ones were also available for analysis, and the same types of EGFR mutations were detected in both the first and second ones in both cases.
  • These findings will be highly informative for treatment of metastatic lung adenocarcinoma to the brain.
  • [MeSH-major] Adenocarcinoma / genetics. Brain Neoplasms / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Cancer. 2007 Apr 15;120(8):1828-31; author reply 1832-3 [17236198.001]
  • (PMID = 16642476.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


28. Compérat E, Zhang F, Perrotin C, Molina T, Magdeleinat P, Marmey B, Régnard JF, Audouin J, Camilleri-Broët S: Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin. Mod Pathol; 2005 Oct;18(10):1371-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin.
  • Thyroid transcription factor-1 (TTF-1) is considered as a reliable marker for differential diagnosis in distinguishing primary adenocarcinomas of the lung from extrathoracic origins.
  • We previously reported the first case of lung metastasis of colorectal origin, with nuclear expression of TTF-1.
  • As most previous studies were performed on series of extrathoracic primary tumors, we raised the question of a possible role of lung microenviroment in TTF-1 expression.
  • We investigated the rate of TTF-1 expression in lung metastases of extrathoracic adenocarcinomas and compared results of immunohistochemistry performed with different primary antibodies.
  • Two different clones of antibodies (8G7G1/1 from Dako, SPT24 from Novocastra) raised against TTF-1 were used on 56 lung-metastatic malignant tumors, 41 from colorectal origin.
  • Four of 41 (10%) lung metastases of colorectal adenocarcinomas displayed a nuclear staining for TTF-1 with SPT24 clone.
  • Three of the four positive cases displayed similar nuclear staining in primary and/or other extrathoracic metastatic sites as well as four of 90 (5%) primary colorectal adenocarcinomas, ruling out the role of lung microenvironment.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Antibodies. Colorectal Neoplasms / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Nuclear Proteins / immunology. Transcription Factors / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861215.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


29. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M: A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol; 2008 Apr;3(4):386-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
  • Vandetanib was evaluated as a monotherapy in a randomized, double-blind, dose-finding study in Japan.
  • PATIENTS AND METHODS: Eligible patients with locally advanced or metastatic (stage IIIB/IV) or recurrent non-small cell lung cancer, previously treated with chemotherapy, were randomized to receive once-daily oral vandetanib 100, 200, or 300 mg (1:1:1).
  • CONCLUSION: In Japanese patients with advanced non-small cell lung cancer, vandetanib monotherapy (100-300 mg/d) demonstrated antitumor activity with an acceptable safety and tolerability profile.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperidines / administration & dosage. Quinazolines / administration & dosage
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Administration, Oral. Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / secondary. Double-Blind Method. Female. Humans. Japan / epidemiology. Male. Maximum Tolerated Dose. Middle Aged. Mutation / genetics. Prognosis. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379357.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


30. Barlési F, Nanni-Metellus I, Breen D, Fina F, Astoul P, Martin PM: Non-small cell lung cancer-smokers or non-smokers, does it matter? Lung Cancer; 2009 Mar;63(3):430-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung cancer-smokers or non-smokers, does it matter?
  • We illustrate the difficulties faced by clinicians with the case of a 56-year-old man with stage IV lung adenocarcinoma and a smoking history of 30-pack-year.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA, Neoplasm / genetics. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics


31. Sato T, Soejima K, Nakayama S, Satomi R, Sayama K, Asano K: [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung]. Nihon Kokyuki Gakkai Zasshi; 2010 Oct;48(10):765-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of fat embolism syndrome associated with pathological femoral fracture caused by metastatic adenocarcinoma of the lung].
  • A 76-year-old woman with multiple bone metastases from lung adenocarcinoma was admitted due to a pathological femoral fracture.
  • Fat embolism syndrome should be considered as a differential diagnosis if consciousness disturbance and respiratory failure occur in patients with metastatic bone carcinoma and pathological long bone fractures.
  • [MeSH-major] Adenocarcinoma / complications. Embolism, Fat / etiology. Femoral Fractures / etiology. Fractures, Spontaneous / etiology. Lung Neoplasms / complications

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066866.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Lysitsas DN, Banerjee P, Shiu MF: Cardiac tamponade because of left atrium direct invasion by a large cell neuroendocrine metastatic carcinoma of the lung. Eur J Echocardiogr; 2008 May;9(3):428-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade because of left atrium direct invasion by a large cell neuroendocrine metastatic carcinoma of the lung.
  • A 53-year-old man presented with cardiac tamponade due to direct invasion of left atrium by a large cell neuroendocrine metastatic lung adenocarcinoma.
  • Direct invasion of left atrial cavity by this type of lung tumour is rare.
  • [MeSH-major] Cardiac Tamponade / etiology. Heart Neoplasms / ultrasonography. Lung Neoplasms / pathology. Neuroendocrine Tumors / ultrasonography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18490347.001).
  • [ISSN] 1532-2114
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Taghva A, Li KW, Liu JC, Gokaslan ZL, Hsieh PC: Minimally invasive circumferential spinal decompression and stabilization for symptomatic metastatic spine tumor: technical case report. Neurosurgery; 2010 Mar;66(3):E620-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive circumferential spinal decompression and stabilization for symptomatic metastatic spine tumor: technical case report.
  • OBJECTIVE: Metastatic epidural spinal cord compression is a potentially devastating complication of cancer and is estimated to occur in 5% to 14% of all cancer patients.
  • Workup revealed metastatic adenocarcinoma of the lung with spinal cord compression at T4 and T5.
  • CONCLUSION: Minimally invasive surgical circumferential decompression may be a viable option for the treatment of metastatic epidural spinal cord compression.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Decompression, Surgical / methods. Humans. Lung Neoplasms / pathology. Male

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173535.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Arabi H, Shah M, Saleh H: Aspiration biopsy cytomorphology of primary pulmonary germ cell tumor metastatic to the brain. Diagn Cytopathol; 2009 Oct;37(10):715-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspiration biopsy cytomorphology of primary pulmonary germ cell tumor metastatic to the brain.
  • Extragonadal germ cell tumors are uncommon and such tumors originating from the lung parenchyma are extremely rare.
  • Her workup revealed two enhancing brain lesions and large lung mass involving the left lower lobe.
  • Fine-needle aspiration (FNA) of the lung followed by craniotomy was performed and the patient was initially diagnosed with lung adenocarcinoma metastatic to the brain based on the cytomorphology of the lung FNA and histology of the brain mass.
  • [MeSH-major] Brain Neoplasms / secondary. Lung Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Biopsy, Fine-Needle. Diagnostic Errors. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19373916.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


35. Farley R, Manolidis S, Ratner D: Adenocarcinoma of the lung metastatic to the skull presenting as a scalp cyst. J Am Acad Dermatol; 2006 May;54(5):916-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the lung metastatic to the skull presenting as a scalp cyst.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Cysts / diagnosis. Lung Neoplasms / pathology. Scalp / pathology. Skull Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16635687.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


36. Dejmek A, Naucler P, Smedjeback A, Kato H, Maeda M, Yashima K, Maeda J, Hirano T: Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol; 2007 Aug;35(8):493-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions.
  • The purpose of this study was to test napsin A as a diagnostic marker of metastatic lung adenocarcinoma in pleural effusions, and to compare its performance with TTF-1.
  • Both markers were negative in 42 cases, including two lung carcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. Lung Neoplasms / diagnosis. Pleural Effusion / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17636482.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


37. Jan IS, Chung PF, Weng MH, Huang MS, Lee YT, Kuo SH: Utility of thyroid transcription factor-1 expression in the differential diagnosis of metastatic adenocarcinoma of serous effusion specimens prepared using the cell transfer technique. J Formos Med Assoc; 2006 Sep;105(9):695-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of thyroid transcription factor-1 expression in the differential diagnosis of metastatic adenocarcinoma of serous effusion specimens prepared using the cell transfer technique.
  • BACKGROUND/PURPOSE: Pulmonary adenocarcinoma is a common malignancy of the pleural cavity.
  • The goal of this study was to investigate the pulmonary origin of metastatic adenocarcinoma by evaluating the immunocytochemical reactivity to thyroid transcription factor-1 (TTF-1) of slides of serous effusion specimens prepared by the cell transfer technique.
  • METHODS: In 2001, a total of 76 archived serous effusion specimens containing adenocarcinoma from patients were used in this study.
  • The primary site of metastatic adenocarcinoma was determined by a review of the medical records.
  • RESULTS: Positive rates of TTF-1 for body fluids collected from patients with lung, stomach, ovarian, breast, colorectal and liver carcinomas were 41/50, 0/11, 0/6, 0/5, 0/2 and 0/1, respectively.
  • Lung adenocarcinoma showed TTF-1 positivity in 82% of specimens, and all other adenocarcinomas had negative TTF-1 staining results.
  • CONCLUSION: This study demonstrated that TTF-1 immunostaining in serous effusion specimens prepared using the cell transfer technique is a sensitive and highly specific marker for metastatic lung adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16959616.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


38. Yeh KH, Yeh SH, Wan JP, Shen YC, Cheng AL: Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. Anticancer Drugs; 2005 Aug;16(7):739-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
  • A 61-year-old never-smoker female suffered from adenocarcinoma of the lung with chest wall invasion and peri-adrenal lymph node metastases.
  • After palliative resection of all clinically detectable primary and metastatic adenocarcinoma, she received cisplatin and gemcitabine combination chemotherapy for a total of 3 cycles.
  • New metastatic lesions were found in spleen and para-aortic lymph nodes.
  • Our patient supports the proposition that somatic mutation L858R in exon 21 of the EGFR gene accounts for complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027522.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin; S65743JHBS / gefitinib
  •  go-up   go-down


39. Gupta A, Raina V, Garg P, Kumar R: Dramatic responses to gefitinib when used as front line therapy in two cases of metastatic lung adenocarcinoma with poor performance status. J Cancer Res Ther; 2010 Jul-Sep;6(3):362-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic responses to gefitinib when used as front line therapy in two cases of metastatic lung adenocarcinoma with poor performance status.
  • A 54-year-old man, a non-smoker, suffering from metastatic lung adenocarcinoma presented with extensive bilateral pulmonary infiltrates.
  • An 80-year-old female, a non smoker, presented with metastatic lung adenocarcinoma and right sided pleural effusion.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119278.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


40. Ghumro MY, Drew L, Tariq SM: An unusual presentation of metastatic adenocarcinoma of lung: a case report. Cases J; 2009;2:9401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of metastatic adenocarcinoma of lung: a case report.
  • We report an unusual patient with primary adenocarcinoma of lung causing malignant pleural and pericardial effusions.
  • The diagnosis was made only at autopsy as his staging computed tomography scan of chest was negative for an obvious mass lesion within the lung or pleura.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Postgrad Med J. 2006 Oct;82(972):642-8 [17068274.001]
  • [Cites] BMJ. 2009;339:b3527 [19773328.001]
  • [Cites] JAMA. 2005 Feb 9;293(6):715-22 [15701913.001]
  • (PMID = 20084189.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2807440
  •  go-up   go-down


41. Thelmo MC, Shen EP, Shertukde S: Metastatic pulmonary adenocarcinoma to placenta and pleural fluid: clinicopathologic findings. Fetal Pediatr Pathol; 2010;29(1):45-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic pulmonary adenocarcinoma to placenta and pleural fluid: clinicopathologic findings.
  • OBJECTIVES: To report the clinicopathologic findings of a pregnant woman with Stage IV adenocarcinoma of the lung with placental metastasis.
  • RESULTS: A 31-year-old G(2)P(1001) woman was diagnosed with Stage IV metastatic adenocarcinoma of the lung.
  • Placental pathology was significant for adenocarcinoma with a solid and acinar pattern, consistent with that from the lung.
  • CONCLUSIONS: The occurance of lung cancer in pregnancy is rare and a few cases have been reported in literature.
  • Placental metastasis is extremely uncommon in these cases and can lead to fetal involvement by lung tumor.
  • It is important to report all cases of lung cancer occurring in pregnancy with subsequent close clinical surveillance of the infant as all cases have a different clinical picture.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Placenta Diseases / pathology. Pleural Effusion, Malignant / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055563.001).
  • [ISSN] 1551-3823
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Zhu W, Michael CW: WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol; 2007 Jun;35(6):370-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
  • The distinction between metastatic adenocarcinomas of lung (LAC), breast (BAC), and ovary (OAC) in serous effusions can be very difficult since they all can present as tight cell clusters.
  • The aim of this study is to evaluate the usefulness of WT1, monoclonal CEA (mCEA), TTF1, and CA125 antibodies in the differential diagnosis of metastatic adenocarcinoma from the lung, breast and ovary in serous effusions.
  • Metastatic OACs showed positive immunoreactivity to WT1 in 19/20 (95%) cases, CA125 in 20/20 (100%), and all showed negative reaction for both mCEA (0/20, 0%) and TTF1 (0/20, 0%).
  • Our results demonstrate that the WT1 stain is specific for metastatic carcinoma of ovarian primary, showing a high sensitivity.
  • A positive TTF1 staining supports the diagnosis of metastatic carcinoma originating from lung rather than breast, while a negative TTF1 favors the diagnosis of a breast primary.
  • Immunohistochemical studies with WT1, TTF1, and mCEA antibodies are useful in the differential diagnosis of metastatic adenocarcinomas of lung, breast, and ovary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. CA-125 Antigen / immunology. Carcinoembryonic Antigen / immunology. Nuclear Proteins / immunology. Pleural Effusion, Malignant / diagnosis. Transcription Factors / immunology. WT1 Proteins / immunology
  • [MeSH-minor] Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497661.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / WT1 Proteins; 0 / thyroid nuclear factor 1
  •  go-up   go-down


43. Shelly MJ, Dheer S, Kavanagh EC: Metastatic adenocarcinoma of the lung mimicking mucoid degeneration of the anterior cruciate ligament. Ir J Med Sci; 2010 Jun;179(2):309-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the lung mimicking mucoid degeneration of the anterior cruciate ligament.
  • We report a case of a 63-year-old male with known adenocarcinoma of the lung who presented with knee pain which was initially diagnosed as mucoid degeneration of the anterior cruciate ligament (ACL) on magnetic resonance imaging (MRI).
  • Due to persistent knee pain an interval MRI was performed, followed by image guided biopsy which showed metastatic adenocarcinoma of the lung infiltrating the ACL.
  • [MeSH-major] Adenocarcinoma / pathology. Anterior Cruciate Ligament / pathology. Knee Joint / pathology. Lung Neoplasms / pathology. Mucins / analysis. Soft Tissue Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 2001 Jun;30(6):312-5 [11465770.001]
  • [Cites] Skeletal Radiol. 2004 Jun;33(6):359-62 [14997351.001]
  • [Cites] Acta Radiol. 2008 Feb;49(1):75-9 [18210315.001]
  • [Cites] J Bone Joint Surg Am. 1992 Mar;74(3):435-7 [1548272.001]
  • [Cites] J Rheumatol. 1977 Spring;4(1):65-72 [886554.001]
  • [Cites] Joint Bone Spine. 2002 Oct;69(5):495-8 [12477235.001]
  • [Cites] Arthroscopy. 1999 Jan-Feb;15(1):98-102 [10024041.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1283-7 [15100133.001]
  • [Cites] J Bone Joint Surg Br. 1999 Mar;81(2):304-5 [10204939.001]
  • (PMID = 19288177.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


44. Liu F, Yu Y, Jin Y, Fu S: TSG101, identified by screening a cancer cDNA library and soft agar assay, promotes cell proliferation in human lung cancer. Mol Biol Rep; 2010 Jul;37(6):2829-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TSG101, identified by screening a cancer cDNA library and soft agar assay, promotes cell proliferation in human lung cancer.
  • A cDNA library of a highly metastatic lung adenocarcinoma cell line was constructed.
  • The expression of TSG101 in lung cancer cell lines and specimens was confirmed using reverse transcription-polymerase chain reaction.
  • Levels of TSG101 mRNA were higher in lung cancer cell lines and specimens compared to matched normal lung tissues.
  • Ectopic expression of TSG101 in the A549 lung adenocarcinoma cell line increased the numbers of cells in S phase, suggesting an increased cell proliferation rate.
  • [MeSH-major] DNA-Binding Proteins / genetics. Endosomal Sorting Complexes Required for Transport / genetics. Gene Library. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 May 3;85(3):319-29 [8616888.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7626-31 [12802020.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3848-54 [17606716.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5950-9 [17369844.001]
  • [Cites] Oncogene. 1998 Feb 5;16(5):677-9 [9482115.001]
  • [Cites] Gut. 2004 Feb;53(2):235-40 [14724156.001]
  • [Cites] J Genet Genomics. 2007 Mar;34(3):189-95 [17498616.001]
  • [Cites] Traffic. 2000 Mar;1(3):248-58 [11208108.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):150-62 [12482969.001]
  • [Cites] Exp Lung Res. 2007 Jun-Jul;33(5):245-58 [17620186.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4830-7 [12101421.001]
  • [Cites] Trends Biochem Sci. 1991 Aug;16(8):301-5 [1957351.001]
  • [Cites] Postepy Biochem. 2005;51(1):44-51 [16209341.001]
  • [Cites] Cancer Biol Ther. 2004 Jun;3(6):561-5 [15044860.001]
  • [Cites] Mol Cell Biol. 1989 Apr;9(4):1799-803 [2542777.001]
  • [Cites] Lung Cancer. 2008 Oct;62(1):35-44 [18355939.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):43216-23 [12205095.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):11735-42 [11134028.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):541-7 [14991575.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3100-4 [7724523.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(1):111-9 [17060450.001]
  • [Cites] Nat Genet. 1997 Aug;16(4):330-1 [9241264.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35984-94 [15210712.001]
  • [Cites] Science. 1987 Oct 9;238(4824):185-8 [3659909.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4225-8 [9331081.001]
  • [Cites] Genes Dev. 2004 Jul 15;18(14 ):1737-52 [15256501.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1736-41 [10749147.001]
  • [Cites] Bull Cancer. 1997 Dec;84(12):1141-2 [9587367.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):269-77 [10888872.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Apr 28;245(3):900-5 [9588212.001]
  • [Cites] J Mol Med (Berl). 1997 Jul;75(7):467-9 [9253709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98 (4):1619-24 [11172000.001]
  • [Cites] Cell. 1997 Jan 10;88(1):143-54 [9019400.001]
  • [Cites] Curr Biol. 2000 Nov 30;10(23):1527-30 [11114522.001]
  • [Cites] Mol Cell Proteomics. 2007 Feb;6(2):294-304 [17110434.001]
  • [Cites] J Cell Biochem. 2001;81(4):621-38 [11329617.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5380-8 [10508170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98 (4):1859-64 [11172041.001]
  • (PMID = 19787439.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Endosomal Sorting Complexes Required for Transport; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / Tsg101 protein
  •  go-up   go-down


45. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Kim HK, Hong EK, Lee JS: Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res; 2005 Apr 15;11(8):3032-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
  • PURPOSE: A subset of patients with adenocarcinoma of the lung who had never smoked cigarettes showed excellent tumor responses to gefitinib therapy.
  • EXPERIMENTAL DESIGN: Eligible patients had no smoking history, stage IIIB or IV adenocarcinoma, Eastern Cooperative Oncology Group performance status 0 to 2, and adequate organ functions.
  • CONCLUSIONS: Gefitinib showed very dramatic antitumor activity, even in the brain, with unprecedented survival outcome in never-smoker adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837758.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


46. Chiu WK, Lin YC, Wang LT, Chen JH, Yu JC, Hsieh CB: Jejunojejunal intussusception secondary to metastasis from adenocarcinoma of the lung--a case report. Acta Chir Belg; 2009 Jul-Aug;109(4):519-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jejunojejunal intussusception secondary to metastasis from adenocarcinoma of the lung--a case report.
  • Small intestine metastasis from primary lung cancer is uncommon and jejunojejunal intussusception secondary to metastatic lung cancer is extremely rare.
  • Chest roentgenogram showed a mass lesion in the right upper lung zone.
  • Biopsy of the lung mass lesion confirmed adenocarcinoma of the lung.
  • Histological examination of the specimen revealed metastatic adenocarcinoma of lung origin.
  • [MeSH-major] Adenocarcinoma / secondary. Intussusception / etiology. Jejunal Diseases / etiology. Jejunal Neoplasms / secondary. Lung Neoplasms / pathology


47. Bahar I, Weinherger D, Kremer MR, Starobin D, Kramer M: [Ocular manifestation of bronchogenic carcinoma: simultaneous occurrence of diffuse uveal melanocytic proliferation and uveal metastases]. Harefuah; 2007 Jan;146(1):2-3, 80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic cancer may affect the eye and orbit as metastatic disease or paraneoplastic retinal degeneration.
  • This is a case report of a 55-year-old man with unilateral visual loss as the presenting symptom of metastatic adenocarcinoma of lung in one eye and diffuse uveal melanocytic proliferation in the other.
  • [MeSH-major] Carcinoma, Bronchogenic / pathology. Lung Neoplasms / pathology. Uvea / pathology. Uveal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294837.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


48. Hariharan S, Zhu J, Nadkarni MA, Donahue JE: Metastatic lung cancer in the cerebellopontine angles mimicking bilateral acoustic neuroma. J Clin Neurosci; 2005 Feb;12(2):184-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lung cancer in the cerebellopontine angles mimicking bilateral acoustic neuroma.
  • However, autopsy showed metastatic adenocarcinoma of the lung.
  • Therefore, metastatic carcinoma to the CPA can mimic bilateral acoustic neuromas; imaging studies alone may be insufficient to diagnose NF-2.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Cerebellopontine Angle / pathology. Lung Neoplasms / pathology


49. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE: Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer; 2007 Apr 1;109(7):1355-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients died, 1 secondary to a complication of metastatic lung adenocarcinoma, and the other of sepsis.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17326049.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


50. Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK: The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol; 2010 Dec 25;118(6):441-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas.
  • BACKGROUND: New developments in the treatment of lung cancer have necessitated the further histologic and cytologic subtyping of nonsmall cell lung carcinomas.
  • Thyroid transcription factor-1 (TTF-1) long has served as the predominant marker for demonstrating lung origin.
  • However, it is also expressed in a variety of other tumors, particularly neuroendocrine neoplasms and, to a much lesser degree, squamous cell carcinoma of the lung.
  • Napsin-A, which is expressed in lung tissue, is a relatively new marker for lung adenocarcinoma.
  • In this study, the authors examined the utility of napsin-A compared with TTF-1 in cytologic specimens of primary and metastatic, poorly differentiated lung adenocarcinomas.
  • METHODS: The archives of the Department of Pathology at The Johns Hopkins Hospital were searched for cytologic cases of poorly differentiated lung adenocarcinoma that were histologically confirmed.
  • Tissue microarrays of lung adenocarcinoma also were examined.
  • CONCLUSIONS: Although TTF-1 had a higher sensitivity, napsin-A was useful as a surrogate marker when encountering a poorly differentiated lung adenocarcinoma or an unknown primary tumor, particularly in cytologic specimens and difficult cases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Aspartic Acid Endopeptidases / analysis. Biomarkers, Tumor / analysis. Lung Neoplasms / diagnosis. Nuclear Proteins / analysis. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20830690.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


51. Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, López A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM: Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clin Cancer Res; 2008 Feb 15;14(4):1116-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient with malignant melanoma had unconfirmed partial response, one patient with metastatic lung adenocarcinoma had minor response, and six patients with different types of metastatic solid tumors had stable disease for 2.8 to 12.7 months.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281545.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; 149204-42-2 / kahalalide F
  •  go-up   go-down


52. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE, Bittigau P, Felderhoff-Mueser U, Kaindl AM, Bührer C, Hansen HH, Stryjecka-Zimmer M, Turski L, Ikonomidou C: NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci U S A; 2005 Oct 25;102(43):15605-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dizocilpine reduces the phosphorylation of cAMP-responsive element binding protein, suppresses the expression of cyclin D1, up-regulates the cell cycle regulators and tumor suppressor proteins p21 and p53, and increases the number of lung adenocarcinoma cells in the G(2) and S phases of the cell cycle.
  • Consistent with inhibition of the extracellular signal-regulated kinase 1/2-signaling cascade, dizocilpine reverses the stimulation of proliferation induced by epidermal, insulin, and basic fibroblast growth factors in lung adenocarcinoma cells.
  • Furthermore, dizocilpine prolongs the survival of mice with metastatic lung adenocarcinoma and slows the growth of neuroblastoma and rhabdomyosarcoma in mice.
  • [MeSH-minor] Cell Proliferation / drug effects. Cells, Cultured. Cyclic AMP Response Element-Binding Protein / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / physiology. Gene Expression Regulation / drug effects. Humans. Lung Neoplasms / drug therapy. Phosphorylation

  • Hazardous Substances Data Bank. DIZOCILPINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurochem. 2001 Nov;79(3):489-98 [11701752.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):599-609 [11483993.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S19-26 [11927283.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):E131-6 [11988758.001]
  • [Cites] Nat Rev Neurosci. 2002 Sep;3(9):748-55 [12209123.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7680-9 [12400010.001]
  • [Cites] Trends Mol Med. 2003 Jan;9(1):36-41 [12524209.001]
  • [Cites] Trends Neurosci. 2003 Feb;26(2):81-9 [12536131.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S155-61 [12867074.001]
  • [Cites] Hum Genet. 2004 Jan;114(2):149-56 [14600829.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1338-46 [14973073.001]
  • [Cites] Neurobiol Dis. 2004 Jul;16(2):440-53 [15193300.001]
  • [Cites] J Pharmacol Exp Ther. 1989 Apr;249(1):278-83 [2540317.001]
  • [Cites] Science. 1993 Apr 2;260(5104):95-7 [8096653.001]
  • [Cites] Annu Rev Neurosci. 1994;17:31-108 [8210177.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9077-81 [7568076.001]
  • [Cites] Science. 1996 Aug 16;273(5277):959-63 [8688081.001]
  • [Cites] J Clin Invest. 1998 Jun 1;101(11):2415-26 [9616213.001]
  • [Cites] J Biol Chem. 1998 Dec 4;273(49):32377-9 [9829964.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):65-72 [15630416.001]
  • [Cites] Brain Res. 2005 Apr 18;1041(2):132-42 [15829222.001]
  • [Cites] Respir Res. 2005;6:29 [15807899.001]
  • [Cites] Life Sci. 2000 Jun 16;67(4):335-64 [11003045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2808-13 [11226322.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6372-7 [11331750.001]
  • [Cites] Curr Opin Neurobiol. 2001 Jun;11(3):327-35 [11399431.001]
  • [Cites] Sci STKE. 2001 May 15;2001(82):pe1 [11752651.001]
  • (PMID = 16230611.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Excitatory Amino Acid Antagonists; 0 / Receptors, N-Methyl-D-Aspartate; 6LR8C1B66Q / Dizocilpine Maleate; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ PMC1266139
  •  go-up   go-down


53. Badia Castello M, Trujillano Cabello J, Serviá Goixart L, Tarragona Foradada J, Panades Siurana MJ, Amoròs Galito E: Occult donor metastatic adenocarcinoma. Contribution of the forensic autopsy. A case report. Ann Transplant; 2010 Jan-Mar;15(1):67-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult donor metastatic adenocarcinoma. Contribution of the forensic autopsy. A case report.
  • The forensic autopsy conducted on the following day revealed a suspicious spot in the lung, on which a biopsy was done.
  • Histological examination confirmed the presence of a metastatic adenocarcinoma in the lung 7 days after both kidneys had been transplanted.
  • [MeSH-major] Adenocarcinoma / etiology. Kidney Transplantation / adverse effects. Neoplasms / etiology. Nephrectomy / adverse effects. Tissue Donors

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305322.001).
  • [ISSN] 2329-0358
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


54. Mendiola C, Vaz MA: Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. Clin Transl Oncol; 2009 Aug;11(8):554-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
  • In lung cancer different histologies have different biologies.
  • Active agents in non-small-cell lung cancer (NSCLC) include platinums, paclitaxel, docetaxel, gemcitabine, erlotinib, pemetrexed and vinorelbine.
  • We report a case of a patient with metastatic lung adenocarcinoma with high levels of LDH and CEA with clear partial response to capecitabine after several lines of chemotherapy.
  • More research is needed to try to explain the striking activity of capecitabine in this patient with lung adenocarcinoma and high levels of CEA and to find molecular targets to predict the response to this agent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Capecitabine. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2000 Mar;27(3):145-57 [10699688.001]
  • [Cites] Lung Cancer. 2009 Feb;63(2):251-8 [18632181.001]
  • [Cites] Oncologist. 2006 Jun;11(6):655-65 [16794244.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1918-24 [14584075.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):481-90 [12189541.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):447-53 [10945489.001]
  • [Cites] Cancer. 2005 Dec 15;104(12 ):2759-65 [16294344.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):379-92 [14736930.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3016-24 [12837811.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):650-4 [15917420.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):12-8 [10458212.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1074-80 [10880550.001]
  • [Cites] Chest. 1994 Sep;106(3):861-5 [7521815.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2464-70 [8640694.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1870-6 [15756012.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • (PMID = 19661033.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


55. But Hadzic J, Secerov A, Zwitter M, Lamovec J, Kern I, Kavsek G, Hergouth KM, De Greve J: Metastatic adenocarcinoma of the lung in a 27-year-old pregnant woman. J Thorac Oncol; 2007 May;2(5):450-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the lung in a 27-year-old pregnant woman.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2007 Jul;2(7):676
  • (PMID = 17473662.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Hanagiri T, Baba T, Ichiki Y, Yasuda M, Sugaya M, Ono K, Uramoto H, Takenoyama M, Yasumoto K: Sleeve lobectomy for patients with non-small cell lung cancer. Int J Surg; 2010;8(1):39-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sleeve lobectomy for patients with non-small cell lung cancer.
  • PURPOSE: A sleeve lobectomy for lung cancer is a procedure intended both for the maintenance of lung function and for radical treatment.
  • We investigated the clinico-pathological features and treatment responses of lung cancer patients who underwent sleeve lobectomy in our department.
  • SUBJECTS: Among the 984 patients with non-small cell lung cancer who underwent resection in our department between 1994 and 2007, the subjects were 24 patients in whom a sleeve lobectomy was performed.
  • The histological type was diagnosed as squamous cell carcinoma in 14 patients, and adenocarcinoma in 10.
  • The pathological stage was evaluated as IA, IB, II, IIIA, IIIB, and IV in 4, 1, 8, 8, 2, and 1 patient, respectively.
  • The 5-year survival rates in squamous cell carcinoma and adenocarcinoma were 83.0% and 45.7%, respectively.
  • CONCLUSION: Sleeve lobectomy facilitated the maintenance of residual lung function without serious perioperative complications.
  • This finding suggests that patients with direct tumor invasion to the bronchus might be good candidates for a sleeve lobectomy, but not those with extra-nodal invasion.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19850158.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Fukuhara T, Saijo Y, Sakakibara T, Inoue A, Morikawa N, Kanamori M, Nakashima I, Nukiwa T: Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med; 2008 Apr;214(4):359-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene.
  • Carcinomatous meningitis is a severe complication of lung cancer.
  • Although treatment with gefitinib, a tyrosine kinase inhibitor of epidermal growth factor (EGF) receptor, has been reported to be highly effective against lung cancers harboring a mutated EGF gene, its effect against carcinomatous meningitis is unknown.
  • Here, we report successful treatment of carcinomatous meningitis with gefitinib in a lung cancer patient suffered from meningeal metastasis.
  • A 62-year-old, non-smoking, Japanese male was admitted for headache, failing vision, and temporary loss of consciousness and was subsequently diagnosed with stage IV lung adenocarcinoma and carcinomatous meningitis.
  • Gefitinib treatment should be considered for patients with carcinomatous meningitis and lung adenocarcinoma harboring a mutated EGF gene.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Agents / administration & dosage. Lung Neoplasms / pathology. Meningeal Neoplasms / drug therapy. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18441512.001).
  • [ISSN] 1349-3329
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


58. Raspollini MR, Comin CE, Crisci A, Chilosi M: The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung. Pathologica; 2010 Feb;102(1):33-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung.
  • Primary bladder adenocarcinoma accounts for 0.5-2% of all malignant bladder tumours.
  • Literature data indicate the bladder as the second most common site of metastatic genitourinary tumours, with the kidney as the most frequent location.
  • Herein, we describe an adenocarcinoma deeply infiltrating the bladder wall, with no morphologic features of transitional cell carcinoma, in a patient with a previous diagnosis of primary lung adenocarcinoma, mixed subtype.
  • In this case, the use of a limited immunohistochemical panel including napsin A, a recently described highly sensitive marker for lung adenocarcinoma, GATA3 and S100P, two novel markers of urothelial differentiation, was of crucial importance in differentiating between lung adenocarcinoma metastatic to the bladder and primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. GATA3 Transcription Factor / metabolism. Lung Neoplasms. S100 Proteins / metabolism. Urinary Bladder Neoplasms

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731252.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / S100 Proteins; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


59. Liam CK, Pang YK, Leow CH: Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. Respirology; 2006 May;11(3):287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
  • OBJECTIVE: To describe the efficacy of monotherapy with the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib in patients with locally advanced and metastatic primary lung adenocarcinoma.
  • METHODS: A retrospective analysis was undertaken of patients who had locally advanced or metastatic lung adenocarcinoma treated with gefitinib 250 mg orally once daily until disease progression.
  • Disease control occurred in 14 patients (61%); there was a reduction in the size of the primary and/or metastatic tumours (partial response (PR)) in 11 patients (48%), and 3 patients (13%) had stable disease.
  • Response was not affected by the patient's age, gender, disease stage, prior chemotherapy treatment, interval between diagnosis and commencement of gefitinib or the development of skin toxicity.
  • CONCLUSION: When given alone, gefitinib showed significant antitumour activity in patients with locally advanced and metastatic primary lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Respirology. 2006 Nov;11(6):835; author reply 836 [17052320.001]
  • (PMID = 16635086.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


60. Preto AS, Teixeira R, Cruz R: [Atypical presentation of lung cancer]. Acta Reumatol Port; 2007 Jul-Sep;32(3):282-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Atypical presentation of lung cancer].
  • [Transliterated title] Apresentação atípica de Neoplasia do Pulmão.
  • Subsequent clinical work-up led to the final diagnosis of stage IV adenocarcinoma of the lung, with bone metastasis.
  • The authors discuss the association between this type of lung neoplasm and osteoarticular manifestations as well as its first presentation as bone metastasis.
  • [MeSH-major] Adenocarcinoma / complications. Bone Neoplasms / secondary. Lung Neoplasms / complications. Osteoarthritis / etiology. Osteoarthritis, Knee / etiology. Wrist Joint


61. Mandelcorn ED, Palestine AG, Dubovy S, Davis JL: Vascular co-option in lung cancer metastatic to the eye after treatment with bevacizumab. J Ophthalmic Inflamm Infect; 2011 Mar;1(1):35-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular co-option in lung cancer metastatic to the eye after treatment with bevacizumab.
  • We present a patient with metastatic lung adenocarcinoma to the eye with findings suggestive of retinal vascular co-option.
  • RESULTS: A 57-year-old male, receiving systemic bevacizumab for metastatic lung adenocarcinoma, presented with vitreous opacities and clumped deposits adherent to the retinal vessels.
  • Diagnostic vitrectomy yielded cellular evidence of adenocarcinoma, with thyroid transcription factor-1 staining confirming a lung primary.
  • CONCLUSION: The perivascular growth of small foci of metastatic vitreous cells suggests vascular co-option from the native retinal circulation.
  • Similar modification of metastatic disease by bevacizumab has been observed in animal models and selected human cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmic Surg Lasers. 2000 Mar-Apr;31(2):155-6 [10743930.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • [Cites] Retina. 1998;18(3):285-6 [9654427.001]
  • [Cites] J Neurooncol. 2010 Feb;96(3):375-84 [19609489.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):363-72 [11224607.001]
  • (PMID = 21475657.001).
  • [ISSN] 1869-5760
  • [Journal-full-title] Journal of ophthalmic inflammation and infection
  • [ISO-abbreviation] J Ophthalmic Inflamm Infect
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3062772
  • [Keywords] NOTNLM ; Angiogenesis / Bevacizumab / Metastatic lung carcinoma / Retina / Vascular co-option / Vitreous
  •  go-up   go-down


62. Sakai M, Oguri T, Sato S, Hattori N, Bessho Y, Achiwa H, Maeda H, Niimi T, Ueda R: Spontaneous hepatic rupture due to metastatic tumor of lung adenocarcinoma. Intern Med; 2005 Jan;44(1):50-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous hepatic rupture due to metastatic tumor of lung adenocarcinoma.
  • A 64-year-old man diagnosed as lung adenocarcinoma with hepatic tumor was admitted to our hospital.
  • He carried the hepatitis B virus but was negative for PIVKA-II and alpha-fetoprotein, and hence we diagnosed a case of stage IV lung adenocarcinoma.
  • Hemorrhagic ascites due to metastatic liver tumor is rare and the sudden onset of abdominal symptoms is an indicator of rupture.
  • [MeSH-major] Adenocarcinoma / secondary. Liver Diseases / etiology. Liver Neoplasms / complications. Liver Neoplasms / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704663.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


63. Chao TC, Chao HH, Jan YY, Chen MF: Perforation through small bowel malignant tumors. J Gastrointest Surg; 2005 Mar;9(3):430-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathology included lymphoma (seven patients), leiomyosarcoma (two patients), gastrointestinal stromal tumor (one patient), adenocarcinoma (one patient), metastatic carcinomas with unknown primary tumor (four patients), metastatic adenocarcinoma from the lung (one patient), and metastatic carcinomas from the hypopharynx (one patient), cervix (one patient), and lung (one patient).

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1988 Feb;6(2):291-6 [3339395.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):267-82 [11588539.001]
  • [Cites] Ann Surg. 1979 Jun;189(6):732-40 [453945.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2157-60 [9951884.001]
  • [Cites] Acta Chir Scand. 1989 Nov-Dec;155(11-12):593-9 [2618515.001]
  • [Cites] Acta Radiol. 1998 Jan;39(1):52-6 [9498870.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Surgery. 2000 Feb;127(2):178-84 [10686983.001]
  • [Cites] Ann Surg. 1996 Jul;224(1):10-8 [8678610.001]
  • [Cites] J Surg Oncol. 1992 Dec;51(4):287-91 [1434663.001]
  • [Cites] Ann Surg. 1980;192(4):581-6 [7425698.001]
  • [Cites] Surgery. 1982 Oct;92(4):605-9 [6981865.001]
  • [Cites] Dis Colon Rectum. 1983 May;26(5):323-6 [6653291.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1999 Feb;66(1):37-40 [10097589.001]
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Arch Surg. 1989 Jul;124(7):830-2 [2742484.001]
  • [Cites] Am Surg. 1989 Jul;55(7):408-12 [2787134.001]
  • [Cites] Surg Today. 2001;31(4):358-62 [11321350.001]
  • [Cites] J Am Coll Surg. 1997 Sep;185(3):250-4 [9291402.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1884-7 [10406253.001]
  • [Cites] J Surg Oncol. 1989 Aug;41(4):219-21 [2666757.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):355-8 [3565679.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]
  • [Cites] J Clin Gastroenterol. 2000 Apr;30(3):289-93 [10777190.001]
  • [Cites] Cancer. 1978 May;41(5):1984-9 [348299.001]
  • [Cites] Ann Surg. 1981 Jan;193(1):67-9 [7458451.001]
  • (PMID = 15749607.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Kostakou C, Khaldi L, Flossos A, Kapsoritakis AN, Potamianos SP: Melena: a rare complication of duodenal metastases from primary carcinoma of the lung. World J Gastroenterol; 2007 Feb 28;13(8):1282-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melena: a rare complication of duodenal metastases from primary carcinoma of the lung.
  • Small bowel metastases from primary carcinoma of the lung are very uncommon and occur usually in patients with terminal stage disease.
  • We describe a case of a 61- year old patient with primary adenocarcinoma of the lung, presenting with melena as the first manifestation of small bowel metastasis.
  • Both primary tumor and metastatic lesions were diagnosed almost simultaneously.
  • Upper gastrointestinal endoscopy performed with a colonoscope revealed active bleeding from a metastatic tumor involving the duodenum and the proximal jejunum.
  • Histological examination and immunohistochemical staining of the biopsy specimen strongly supported the diagnosis of metastatic lung adenocarcinoma, suggesting that small bowel metastases from primary carcinoma of the lung occur usually in patients with terminal disease and rarely produce symptoms.
  • Gastrointestinal bleeding from metastatic small intestinal lesions should be included in the differential diagnosis of gastrointestinal blood loss in a patient with a known bronchogenic tumor.
  • [MeSH-major] Adenocarcinoma / secondary. Duodenal Neoplasms / secondary. Lung Neoplasms / pathology. Melena / etiology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 1999 Nov;26(2):95-101 [10568680.001]
  • [Cites] Intern Med. 2006;45(16):967-70 [16974060.001]
  • [Cites] Dig Liver Dis. 2002 Feb;34(2):141-3 [11926559.001]
  • [Cites] Kyobu Geka. 2004 Feb;57(2):151-3 [14978913.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1486-9 [3028602.001]
  • [Cites] Am J Gastroenterol. 1991 Jun;86(6):771-4 [2039005.001]
  • [Cites] Acta Gastroenterol Belg. 1996 Jul-Sep;59(3):217-9 [9015935.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1884-7 [10406253.001]
  • [Cites] Surg Today. 1999;29(8):799-802 [10483762.001]
  • [Cites] World J Gastroenterol. 2005 Mar 7;11(9):1399-402 [15761985.001]
  • [Cites] Ann Nucl Med. 2005 Apr;19(2):161-3 [15909498.001]
  • [Cites] Am Surg. 2005 Feb;71(2):110-6 [16022008.001]
  • [Cites] Tumori. 2006 Mar-Apr;92(2):185-7 [16724702.001]
  • [Cites] Rev Mal Respir. 2006 Jun;23(3 Pt 1):273-6 [16788529.001]
  • [Cites] Surg Today. 2001;31(4):358-62 [11321350.001]
  • (PMID = 17451216.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4147010
  •  go-up   go-down


65. Kagohashi K, Satoh H, Ohtsuka M: Gefitinib is an additional prognostic factor in metastatic lung adenocarcinoma. Respirology; 2006 Nov;11(6):835; author reply 836
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib is an additional prognostic factor in metastatic lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Respirology. 2006 May;11(3):287-91 [16635086.001]
  • (PMID = 17052320.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


66. Tazi N, Le Thi Huong D, Bodaghi B, Rixe O, Lehoang P, Piette JC: [Choroidal metastasis revealing pulmonary adenocarcinoma]. Rev Med Interne; 2006 Sep;27(9):699-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis revealing pulmonary adenocarcinoma].
  • Lung cancer is the first cause of choroidal metastasis in man.
  • Generally, its discovery is made at end-stage of the disease.
  • He presented with visual decrease and metamorphopsia that lead to the diagnosis of a metastatic adenocarcinoma of the lung (bone, liver, choroid, nodles).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872723.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


67. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC: Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol; 2006 Jan;3(1):50-7; quiz 1 p following 57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
  • BACKGROUND: A 70-year-old Japanese-American woman who had never smoked was diagnosed with stage IV non-small-cell lung cancer with rib metastases.
  • DIAGNOSIS: Erlotinib-refractory stage IV lung adenocarcinoma and end-stage symptomatic leptomeningeal metastases with a novel double L858R + E884K somatic mutation of the EGFR.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Meningeal Neoplasms / secondary. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics. Ribs / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407879.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


68. Raz O, Stav K, Mendlovic S, Bar I, Zisman A: Exceptional site of metastatic adenocarcinoma of the lung. Isr Med Assoc J; 2007 Feb;9(2):119-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exceptional site of metastatic adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17348487.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


69. Sawada T, Takahashi H, Hasatani K, Yoshida I, Oyama O, Inoue R, Miwa K, Kawashiri MA, Misawa K, Kyoi M, Miyamoto S: Tumor-to-tumor metastasis: report of an autopsy case of lung adenocarcinoma metastasizing to renal cell carcinoma. Intern Med; 2009;48(17):1525-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis: report of an autopsy case of lung adenocarcinoma metastasizing to renal cell carcinoma.
  • Lung cancer metastatic to renal cell carcinoma represents the most common combination of such tumor-to-tumor metastases.
  • We present the autopsy case of a 97-year-old woman with metastatic adenocarcinoma of the lung to renal cell carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / diagnosis. Kidney Neoplasms / secondary. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19721297.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 19
  •  go-up   go-down






Advertisement